50877-42-4

Basic information

• Product Name: 1-Benzyl-4-iodo-1H-pyrazole
• Synonyms: 1-BENZYL-4-IODO-1H-PYRAZOLE;1H-(N-BENZYL)-4-IODOPYRAZOLE;1-Benzyl-4-iodo-1H-pyraole;benzyl-4-iodo-1H-pyrazole;1H-pyrazole, 4-iodo-1-(phenylmethyl)-;4-Iodo-1-benzyl-1H-pyrazole, 95%;1-(benzyl)-4-iodo-pyrazole;4-iodo-1-(phenylmethyl)pyrazole
• CAS NO: 50877-42-4
• Molecular Formula: C₁₀H₉IN₂
• Molecular Weight: 284.1
• Product Categories: Halides;Pyrazoles & Triazoles;Halogenated;Organohalides;Pyrazole;Pyrazoles & Triazoles;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyrazoles;PyrazolesHeterocyclic Building Blocks
• Mol File: 50877-42-4.mol

Chemical Properties

• Melting Point: 63-66°C
• Boiling Point: 367.1 °C at 760 mmHg
• Flash Point: 175.8 °C
• Appearance: /
• Density: 1.67 g/cm³
• Vapor Pressure: 2.95E-05mmHg at 25°C
• Refractive Index: 1.667
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 0.11±0.10(Predicted)
• CAS DataBase Reference: 1-Benzyl-4-iodo-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-4-iodo-1H-pyrazole(50877-42-4)
• EPA Substance Registry System: 1-Benzyl-4-iodo-1H-pyrazole(50877-42-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-41-37/38
• Safety Statements: 26-36-39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 50877-42-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-4-iodo-1H-pyrazole is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity enable the development of new drugs with improved therapeutic properties and reduced side effects.
Used in Agrochemical Industry:
1-Benzyl-4-iodo-1H-pyrazole is utilized as a building block for the synthesis of agrochemicals, such as pesticides and herbicides. Its versatility allows for the creation of novel compounds with enhanced efficacy and selectivity, contributing to more sustainable agricultural practices.
Used in Specialty Chemicals Industry:
1-Benzyl-4-iodo-1H-pyrazole serves as a valuable intermediate in the production of specialty chemicals, including dyes, fragrances, and other high-value compounds. Its unique properties enable the development of innovative products with superior performance and application potential.
Used in Medicinal Chemistry Research:
1-Benzyl-4-iodo-1H-pyrazole is employed as a versatile chemical intermediate in medicinal chemistry research. Its structure and reactivity facilitate the exploration of new chemical space and the discovery of novel bioactive compounds with potential therapeutic applications.
Used in Chemical Research:
1-Benzyl-4-iodo-1H-pyrazole is utilized in chemical research to study various reaction mechanisms and explore new synthetic methodologies. Its unique properties provide insights into the reactivity of heterocyclic compounds and contribute to the advancement of organic chemistry.

InChI:InChI=1/C10H9IN2/c11-10-6-12-13(8-10)7-9-4-2-1-3-5-9/h1-6,8H,7H2

Upstream product

• 3469-69-0 4-iodopyrazole 
• 100-44-7 benzyl chloride 
• 10199-67-4 1-benzylpyrazole 
• 100-39-0 benzyl bromide 
• 7646-69-7 sodium hydride 
• 71759-89-2 4-iodoimidazole 
• 852362-22-2 (1-benzyl-1H-pyrazol-4-yl)boronic acid 
• 1007468-14-5 N-benzyl-4-iodopyrazole diacetate 
• 762-72-1 allyl-trimethyl-silane 

Downstream Products

• 88095-61-8 1-benzyl-4-nitro-1H-pyrazole 
• 1326316-19-1 4-allyloxy-1-benzyl-1H-pyrazole 
• 226989-35-1 1-benzyl-4-hydroxy-1H-pyrazole 
• 1326316-24-8 C₁₃H₁₄N₂O 
• 1326316-31-7 3,5-diallyl-2-benzyl-4-hydroxy-2H-pyrazole 
• 63874-95-3 1-benzyl-1H-pyrazole-4carboxaldehyde 
• 1352655-02-7 tert-butyl 3-(1-benzyl-1H-pyrazol-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 761446-45-1 1-(phenylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1310452-48-2 1-benzyl-4-(2-methoxycarbonylvinyl)-1H-pyrazole 
• 1266358-11-5 1-benzyl-4-(4-(1-benzyl-1H-pyrazol-4-yl)buta-1,3-diynyl)-1H-pyrazole 

Relevant articles and documents

BTK Inhibitors and uses thereof

The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.

Copper-catalyzed and additive free decarboxylative trifluoromethylation of aromatic and heteroaromatic iodides

A copper-catalyzed decarboxylative trifluoromethylation of (hetero)aromatic iodides has been developed. Importantly, this new copper-catalyzed reaction operates in the absence of any ligands and metal additives. The protocol shows good functional group tolerance and is compatible with heteroaromatic systems. The reaction proved scalable to a 15 mmol scale with increased yield. Finally, late-stage installation of the trifluoromethyl functionality afforded the N-trifluoroacetamide variant of the antidepressant agent, Prozac, demonstrating the applicability of the developed method.

Mechanism of Cu-catalyzed aryl boronic acid halodeboronation using electrophilic halogen: Development of a base-catalyzed iododeboronation for radiolabeling applications

An investigation into the mechanism of Cu-catalyzed aryl boronic acid halodeboronation using electrophilic halogen reagents is reported. Evidence is provided to show that this takes place via a boronate-driven ipso-substitution pathway and that Cu is not required for these processes to operate: General Lewis base catalysis is operational. This in turn allows the rational development of a general, simple, and effective base-catalyzed halodeboronation that is amenable to the preparation of 125I-labeled products for SPECT applications.

Transition-metal-free hydrogenation of aryl halides: From alcohol to aldehyde

A transition-metal-and catalyst-free hydrogenation of aryl halides, promoted by bases with either aldehydes or alcohols, is described. One equivalent of benzaldehyde affords an equal yield as that of 0.5 equiv of benzyl alcohol. The kinetic study reveals that the initial rate of PhCHO is much faster than that of BnOH, in the ratio of nearly 4:1. The radical trapping experiments indicate the radical nature of this reaction. Based on the kinetic study, trapping and KIE experiments, and control experiments, a tentative mechanism is proposed. As a consequence, a wide range of (hetero)aryl iodides and bromides were efficiently reduced to their corresponding (hetero)arenes. Thus, for the first time, aldehydes are directly used as hydrogen source instead of other well-established alcohol-hydrogen sources.

A 1-alkyl-pyrazol-4-boronic acid frequency method for the synthesis of ester

The invention belongs to the field of organic chemical synthesis and provides a synthetic method of 1-alkylpyrazole-4-boronic acid pinacol ester. The synthetic method comprises the following three steps: 1. reacting pyrazole with iodine and hydrogen peroxide to generate 4-iodopyrazole A; 2. reacting the 4-iodopyrazole with alkyl halide to obtain an intermediate B; 3. preparing a Grignard reagent of the raw material by using 1-alkyl-4-iodopyrazole as a raw material and adopting an isopropyl Grignard reagent exchange method at 0-30 DEG C, with BE001 as a boron reagent, and reacting to obtain the final product. The technological method is accessible in raw materials, simple and convenient to operate and lower in cost and is a proper method for preparing 1-alkylpyrazole-4-boronic acid pinacol ester compounds.

HETEROARYL COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF

The present invention provides herein is a heteroaryl compound or a stereoisomer, a geometric isomer, a tautomer, a racemate, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, as well as a pharmaceutical composition containing the compound disclosed herein. The present invention also provides herein is use of the compound or the pharmaceutical composition thereof disclosed herein in the manufacture of a medicine for treating autoimmune diseases or proliferative diseases.

2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE

Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR4; A2 is selected from:, a C5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are β to one another; L1 is selected from: (i)A1-O-CH2-A2; (ii)A1-CH2-O-A2; (iii)A1-C(=O)-NH-A2; (iv)A1-CH(OH)-A2; (v)A1-CH2-NH-C(=O)-A2; (vi) A1-S-CH2-A2; (vii)A1- CH2-S-A2; (viii)A1-CH2-A2; and (ix)A1-CH(CH3)-O-A2; A1 is phenyl, optionally substituted by F or CF3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.

[1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUND, PREPARATION METHOD AND USE THEREOF

The present invention relates to a structurally novel [1,2,4]triazolo[4,3-b][1,2,4]triazine compounds represented by formula (I) or formula (II), pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates or solvates thereof, and also relates to a preparation method of the compounds, a pharmaceutical composition comprising a therapeutically effective amount of the compounds, as well as the use thereof as protein tyrosine kinase inhibitors, particularly as c-Met inhibitors, in the preparation of medicaments for the prevention and/or treatment of diseases associated with c-Met abnormality.

Reductive iodonio-Claisen rearrangement of iodothiophene diacetates with allylsilanes: Formal synthesis of Plavix

Iodothiophene diacetates react with allyltrimethylsilanes in the presence of boron trifluoride diethyl etherate to afford corresponding ortho-allyliodothiophenes via reductive iodonio-Claisen rearrangement. This method has been successfully applied to the synthesis of Plavix, a blood clot inhibitor used to reduce the risk of heart attack and stroke.

Carbazole inhibitors of histamine receptors for the treatment of disease

The present invention relates to carbazole compounds, pharmaceutical compositions comprising them, and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.